ストックスクリーナーアプリを入手
55.94
2.08%
1.14
アフターアワーズ：
59.06
3.12
+5.58%
Halozyme Therapeutics Inc (HALO) 最新ニュース
AMI Asset Management Corp Has $1.79 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Sugar Maple Asset Management LLC Invests $373,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Sees Large Growth in Short Interest - MarketBeat
Empirical Asset Management LLC Invests $1.09 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Bernzott Capital Advisors Invests $4.49 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Outlook Wealth Advisors LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Converting IV-drip Medications into Shots -January 16, 2025 at 12:29 pm EST - Marketscreener.com
(HALO) Technical Data - Stock Traders Daily
Research Analysts Offer Predictions for HALO FY2025 Earnings - MarketBeat
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
Wells Fargo & Company Has Lowered Expectations for Halozyme Therapeutics (NASDAQ:HALO) Stock Price - Defense World
5 Biotech Stocks Worth Adding to Your Portfolio in 2025 - Zacks Investment Research
Q1 Earnings Forecast for HALO Issued By Leerink Partnrs - MarketBeat
Analyst Expectations For Halozyme Therapeutics's Future - Benzinga
Halozyme Therapeutics (NASDAQ:HALO) Price Target Cut to $57.00 by Analysts at Wells Fargo & Company - MarketBeat
Analysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) Price Target at $61.44 - MarketBeat
Piper Sandler Increases Halozyme Therapeutics (NASDAQ:HALO) Price Target to $53.00 - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Halozyme Therapeutics (NASDAQ:HALO) Stock - Defense World
HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up - MSN
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why - MSN
Halozyme raises 2025 guidance, announces $250M stock buyback - MSN
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $53.00 - MarketBeat
Q3 EPS Estimate for Halozyme Therapeutics Lifted by Analyst - MarketBeat
Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock? - MSN
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Q1 EPS Forecast for Halozyme Therapeutics Raised by Analyst - MarketBeat
Earnings call transcript: Halozyme Q3 2024 boosts guidance amid strong growth - Investing.com India
First Hawaiian Bank Purchases 20,700 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Everence Capital Management Inc. Purchases New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
Halozyme Therapeutics (NASDAQ:HALO) Shares Gap UpTime to Buy? - MarketBeat
Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia - Kilgore News Herald
Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2025 Earnings Guidance - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2024 Earnings Guidance - MarketBeat
Halozyme Therapeutics, Inc. Raises Earnings Guidance for the Full Year 2025 -January 08, 2025 at 07:00 am EST - Marketscreener.com
Halozyme Therapeutics (NASDAQ:HALO) Updates FY24 Earnings Guidance - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Releases FY25 Earnings Guidance - MarketBeat
Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Full Year 2024 - Marketscreener.com
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance - PR Newswire
Halozyme Therapeutics director Jeffrey Henderson sells $500,060 in stock - Investing.com India
Insider Sell: Jeffrey Henderson Sells 10,000 Shares of Halozyme Therapeutics Inc (HALO) - GuruFocus.com
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson Sells 10,000 Shares - MarketBeat
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks - Yahoo Finance
Zacks.com featured highlights include Leidos, Amazon.com, Halozyme Therapeutics and BioMarin Pharmaceutical - Yahoo Finance
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance - The Malaysian Reserve
Halozyme Therapeutics (HALO) Shares Cross Above 200 DMA - Nasdaq
Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025 - Seeking Alpha
Halozyme: Recent Approvals Alter My Appetite (NASDAQ:HALO) - Seeking Alpha
FDA Approves BMS’ Opdivo Qvantig with Halozyme’s ENHANZE Technology - Contract Pharma
4.81%
大文字化:
|
ボリューム (24 時間):